14 October 2022 : Clinical Research
Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer
Zin W. Myint12ABCDEFG*, Jill M. Kolesar23CDE, Joseph Robert McCorkle2CDE, Jianrong Wu4C, Carleton S. Ellis32CDE, Danielle E. Otto23CDE, Peng Wang12ACDEDOI: 10.12659/MSM.938091
Med Sci Monit 2022; 28:e938091
Table 1 Patient baseline characteristics.
| Characteristics | # (Range) | % |
|---|---|---|
| Total patients enrolled | 13 | |
| Median age, years (range) | 64 (56–83) | |
| Ethnicity | ||
| White | 11 | 85% |
| African-American | 2 | 15% |
| Median body mass index, kg/m (range) | 30.1 (20.7–38.7) | |
| Obese | 8 | 62% |
| Non-obese | 5 | 38% |
| ECOG performance status | ||
| 0 | 4 | 31% |
| 1 | 6 | 46% |
| 2 | 3 | 23% |
| Received previous treatment | ||
| Yes | 3 | 23% |
| No | 10 | 77% |
| Median PSA (ng/mL) (range) | 132 (57–4279) | |
| Volume of disease | ||
| High | 10 | 77% |
| Low | 3 | 23% |
| ECOG – Eastern Cooperative Oncology Group; PSA – prostate-specific antigen; # – number. | ||